Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
McKesson ( (MCK) ) just unveiled an announcement.
McKesson Corporation said on March 6, 2026, that it will release its fourth quarter fiscal 2026 results after market close on May 7, 2026, followed by a webcasted earnings call led by CEO Brian Tyler and CFO Britt Vitalone. The company also reaffirmed its fiscal 2026 full-year outlook and highlighted Vitalone’s participation in several major healthcare investor conferences in March and May, underscoring its ongoing engagement with the investment community through webcasts available on its investor relations site.
The most recent analyst rating on (MCK) stock is a Hold with a $925.00 price target. To see the full list of analyst forecasts on McKesson stock, see the MCK Stock Forecast page.
Spark’s Take on MCK Stock
According to Spark, TipRanks’ AI Analyst, MCK is a Outperform.
The score is driven by strong cash-flow fundamentals and a very constructive earnings outlook with raised FY2026 guidance. These positives are tempered by a weaker balance-sheet profile and an extended technical condition (high RSI), while valuation is only modestly supportive due to a low dividend yield.
To see Spark’s full report on MCK stock, click here.
More about McKesson
McKesson Corporation is a diversified healthcare services leader that partners with biopharma companies, care providers, pharmacies, manufacturers and governments to advance health outcomes. The company delivers insights, products and services aimed at making quality care more accessible and affordable, impacting virtually every aspect of the healthcare system.
Average Trading Volume: 721,123
Technical Sentiment Signal: Buy
Current Market Cap: $114.1B
For detailed information about MCK stock, go to TipRanks’ Stock Analysis page.